ReviewBiomedicines2022
Hypersensitivity Reactions to Iodinated Contrast Media.
Review in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 47 citations in OpenAlex.
- Negative Predictive Value of Allergologic Work-Up with Iodinated Contrast Media in 'Real-Life' Practice.Journal of clinical medicine · 2026Article
- Anaphylactic Shock Following Administration of Iodinated Computed Tomography (CT) Contrast Media: A Case Series.Cureus · 2026Article
- Characterization and diagnostic evaluation of hypersensitivity to iodinated contrast media: A retrospective analysis.The World Allergy Organization journal · 2026Article
- Genetic variations associated with immediate hypersensitivity reactions to iodinated contrast media: A whole exome sequencing study.PloS one · 2026Article
- Investigating the Experiences and Self-Reported Abilities of Diagnostic Radiographers in Responding to Contrast-Induced Reactions Associated With Computed Tomography Examinations: A Cross-Sectional Survey.Health science reports · 2026Article
- Adverse Reactions to CT Contrast Agents: A 10-Year Study of Clinical and Environmental Risk Factors.Diagnostics (Basel, Switzerland) · 2025Article
- Risk factor analysis of iodinated contrast medium-related hypersensitivity reactions.Insights into imaging · 2025Review
- Research on Denoising Methods for Magnetocardiography Signals in a Non-Magnetic Shielding Environment.Sensors (Basel, Switzerland) · 2025Article
- Testicular varicocele embolization using CO2, gadolinium and lipiodol as contrast agents in a patient with an iodinated contrast allergy.Radiology case reports · 2025Article
- Characterization of Hypersensitivity to Iodinated Contrast Media: Insights from a Six-Year Cohort of 26,465 Procedures.Healthcare (Basel, Switzerland) · 2025Article
- Hypersensitivity Reactions to Iodinated Contrast Media: A Narrative Review of Current Evidence and Clinical Challenges.Healthcare (Basel, Switzerland) · 2025Review
- Classification of carotid artery plaques: promising alternative methods to computed tomography angiography through radiomics approach using neck non-contrast computed tomography.Quantitative imaging in medicine and surgery · 2025Article
- Risks and Benefits of Cervical Transforaminal Epidural Steroid Injections: A Comprehensive Review.Current pain and headache reports · 2025Review
- Hypersensitivity reactions to iodinated contrast media: potential mechanisms and clinical management.Frontiers in medicine · 2025Review
- Drug provocation tests (DPTs) of contrast media: Useful or not useful? - A narrative review.The World Allergy Organization journal · 2024Review
- Drug-Induced Anaphylaxis: National Database Analysis.Pharmaceuticals (Basel, Switzerland) · 2024Article
- The Diverse Utility of Contrast Media Delivery and Dosing During Computed Tomography: An International Assessment of Knowledge and Practices.Current radiopharmaceuticals · 2024Article
- Stroke in a patient of anaphylaxis-a case report and brief review.International journal of emergency medicine · 2023Article
- Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension: a clinical consensus statement of the ESC working group on pulmonary circulation and right ventricular function.European heart journal · 2023Article
- Alveolar Hemorrhage Following Positron Emission Tomography/Computed Tomography in 2 Separate Episodes 5 Months Apart.The American journal of case reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
At present, iodinated contrast media (ICM) are mostly non-ionic, have low osmolality, and are safe. Even if adverse drug reactions (ADRs) occur, most are chemo-toxic symptoms and require only observation or H1 antihistamines. However, rare, unpredictable, and even life-threatening hypersensitivity can still occur. The aim of this review is to summarize the issues that all relevant staff need to know about and be able to respond to. The most significant risk factor for ICM hypersensitivity is a history of ICM hypersensitivity. For high-risk populations, we must cautiously weigh the advantages and disadvantages of premedication and be aware that breakthrough reactions may still occur. The best policy for patients with a history of severe ICM hypersensitivity is to avoid the same ICM. If ICM are inevitable, skin tests, in vitro tests, and drug provocation tests may help to find a feasible alternative that is safer. The severity of the hypersensitivity is correlated with the positivity rate of these tests, so there is no need for further investigations for patients with only mild reactions. We should also keep in mind that even excipients in ICM may induce hypersensitivity. Detailed, standardized documentation is essential for correct diagnosis and the prevention of future occurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.